A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

NCT04012255 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

29

Enrollment

INDUSTRY

Sponsor class

Stopped The trial was terminated for strategic reasons.

Conditions

Overweight
Obesity

Interventions

DRUG: Semaglutide (administered by DV3396 pen)
DRUG: Semaglutide (administered by PDS290 pen)

Sponsor

Novo Nordisk A/S